Enavate Sciences GP, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001953107

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth Tilt how tags are computed

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024

Q2 2026 · 7 positions · Total reported value $345.38M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 14.3% · 0 new · 1 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): -0.8% · vs SPY -15.6% · Prev Value $351.51M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Enavate Sciences GP, LLC disclosed 7 equity positions with a combined reported value of $345.38M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt.

The largest disclosed positions as of Q2 2026 were SION ($109.01M), ZBIO ($99.47M), IMNM ($76.58M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Enavate Sciences GP, LLC opened 0 new positions, trimmed 1 and fully exited 0, a turnover rate of 14.3% of positions. The portfolio's overlap with the prior quarter was 100% of names.

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

Insider Transactions (Form 4)

Latest Enavate Sciences GP, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Enavate Sciences GP, LLC is an SEC-registered 13F filer. As of Q2 2026 it reported 7 US equity positions with a combined value of $345.38M. HoldingsHub carries 7 quarters of its filings (Q4 2024–Q2 2026).

Portfolio Structure

  • 7 positions · $345.38M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: SION (SIONNA THERAPEUTICS INC) at 31.6%
  • Average position size: $49.34M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 reduced
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a conservative stance, with a focus on healthcare sector investments. The lack of changes in positions suggests a defensive approach in the face of potential market volatility. 2. Key Moves: - Added/Reduced: No new positions were added; however, there was a significant reduction in the position of CAMP4 THERAPEUTICS CORP (CAMP) from 2,190,920 to 1,425,541 shares, representing a 34.9% decrease quarter-over-quarter. - Holdings: The fund maintained its positions in SIONNA THERAPEUTICS INC COM (SION), ZENAS BIOPHARMA INC (ZBIO), IMMUNOME INC (IMNM), BridgeBio Oncology Therapeutic (BBOT), COMPASS THERAPEUTICS INC (CMPX), and UPSTREAM BIO INC (UPB) without any changes in share count or weight. 3. Portfolio Structure: - Passive/Active: The fund seems to have a passive structure, as there were no additions or significant changes to its holdings. - Sector Bias: The portfolio is heavily biased towards the healthcare sector, reflecting a sector-specific investment strategy. - Risk Appetite: The low turnover and conservative approach indicate a low risk appetite, with a preference for stability and long-term investments. 4. Per-Holding One-Liner: - SIONNA THERAPEUTICS INC COM (SION): Develops therapies for rare and orphan diseases. - ZENAS BIOPHARMA INC (ZBIO): Focuses on the development of novel treatments for cancer and rare genetic diseases. - IMMUNOME INC (IMNM): Engages in the development of personalized immunotherapies. - BridgeBio Oncology Therapeutic (BBOT): Specializes in developing treatments for rare genetic diseases. - COMPASS THERAPEUTICS INC (CMPX): Focuses on the development of novel therapies for rare genetic diseases. - UPSTREAM BIO INC (UPB): Engages in the discovery and development of novel therapies for oncology and rare diseases. - CAMP4 THERAPEUTICS CORP (CAMP): Develops therapies for rare and orphan diseases. (unverified) 5. One-Sentence Style Summary: The Enavate Sciences GP, LLC fund maintained a stable healthcare sector focus in Q2 2026, showing a conservative approach with minimal rebalancing and a preference for long-term investments.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.48M $109.01M 31.56%
31.56%
Hold
2 3.92M $99.47M 28.80%
28.80%
Hold
3 3.61M $76.58M 22.17%
22.17%
Hold
4 2.63M $20.02M 5.80%
5.80%
Hold
5 7.79M $17.06M 4.94%
4.94%
Hold
6 2.46M $17.02M 4.93%
4.93%
Hold
7 1.43M $6.23M 1.80%
1.80%
Reduce

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 100% R 100% F1 100% (modelled on 2026-Q1; 7/10 hit)

Historical Backtest (5 quarters)

Avg precision 100% · recall 97% · F1 98% · avg rank error 0.9 · Top-10 turnover 0%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2025-Q2 100% 100% 100% IMNM · ZBIO · SION · CAMP · UPB · CMPX IMNM · SION · ZBIO · UPB · CMPX · CAMP
2025-Q3 100% 86% 92% IMNM · SION · ZBIO · UPB · CMPX · CAMP ZBIO · SION · IMNM · UPB · BBOT · CMPX · CAMP
2025-Q4 100% 100% 100% ZBIO · SION · IMNM · UPB · BBOT · CMPX · CAMP ZBIO · IMNM · SION · UPB · CMPX · BBOT · CAMP
2026-Q1 100% 100% 100% ZBIO · IMNM · SION · UPB · CMPX · BBOT · CAMP SION · IMNM · ZBIO · CMPX · BBOT · UPB · CAMP
2026-Q2 ★ 100% 100% 100% SION · ZBIO · IMNM · CMPX · BBOT · UPB · CAMP SION · ZBIO · IMNM · BBOT · CMPX · UPB · CAMP

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Enavate Sciences GP, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Enavate Sciences GP, LLC reported 7 equity positions worth $345.38M in aggregate; its largest disclosed positions were SION ($109.01M), ZBIO ($99.47M), IMNM ($76.58M).

How large is Enavate Sciences GP, LLC's portfolio?

Enavate Sciences GP, LLC reported $345.38M of long equity holdings across 7 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is Enavate Sciences GP, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/enavate-sciences-gp/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →